Original ArticleOriginal Article
Open Access

Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer

Ming Bai, Yao Lu, Chunmei Shi, Jianwei Yang, Wei Li, Xianli Yin, Chenghui Huang, Lin Shen, Liangzhi Xie and Yi Ba
Cancer Biology & Medicine July 2024, 21 (7) 636-650; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0301

References

  1. 1.↵
    2. Bray F,
    3. Ferlay J,
    4. Soerjomataram I,
    5. Siegel RL,
    6. Torre LA,
    7. Jemal A.
    Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Goldberg RM,
    3. Sargent DJ,
    4. Morton RF,
    5. Fuchs CS,
    6. Ramanathan RK,
    7. Williamson SK, et al.
    A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22: 23–30.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    2. Douillard JY,
    3. Cunningham D,
    4. Roth AD,
    5. Navarro M,
    6. James RD,
    7. Karasek P, et al.
    Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355: 1041–7.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    2. Jiang Y,
    3. Yuan H,
    4. Li Z,
    5. Ji X,
    6. Shen Q,
    7. Tuo J, et al.
    Global pattern and trends of colorectal cancer survival: a systematic review of population-based registration data. Cancer Biol Med. 2021; 19: 175–86.
    OpenUrl
  5. 5.↵
    2. Yamazaki K,
    3. Nagase M,
    4. Tamagawa H,
    5. Ueda S,
    6. Tamura T,
    7. Murata K, et al.
    Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016; 27: 1539–46.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Li J,
    3. Qin S,
    4. Xu RH,
    5. Shen L,
    6. Xu J,
    7. Bai Y, et al.
    Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018; 319: 2486–96.
    OpenUrlCrossRefPubMed
  7. 7.
    2. Grothey A,
    3. Van Cutsem E,
    4. Sobrero A,
    5. Siena S,
    6. Falcone A,
    7. Ychou M, et al.
    Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381: 303–12.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.
    2. Xu J,
    3. Kim TW,
    4. Shen L,
    5. Sriuranpong V,
    6. Pan H,
    7. Xu R, et al.
    Results of a randomized, double-blind, placebo-controlled, phase III trial of Trifluridine/Tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018; 36: 350–8.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Mayer RJ,
    3. Van Cutsem E,
    4. Falcone A,
    5. Yoshino T,
    6. Garcia-Carbonero R,
    7. Mizunuma N, et al.
    Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372: 1909–19.
    OpenUrlCrossRefPubMed
  10. 10.↵
    2. Le DT,
    3. Kim TW,
    4. Van Cutsem E,
    5. Geva R,
    6. Jager D,
    7. Hara H, et al.
    Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020; 38: 11–9.
    OpenUrlCrossRefPubMed
  11. 11.
    2. Overman MJ,
    3. McDermott R,
    4. Leach JL,
    5. Lonardi S,
    6. Lenz HJ,
    7. Morse MA, et al.
    Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017; 18: 1182–91.
    OpenUrlCrossRefPubMed
  12. 12.↵
    2. Overman MJ,
    3. Lonardi S,
    4. Wong KYM,
    5. Lenz HJ,
    6. Gelsomino F,
    7. Aglietta M, et al.
    Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018; 36: 773–9.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. Le DT,
    3. Uram JN,
    4. Wang H,
    5. Bartlett BR,
    6. Kemberling H,
    7. Eyring AD, et al.
    PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372: 2509–20.
    OpenUrlCrossRefPubMed
  14. 14.↵
    2. Bao X,
    3. Zhang H,
    4. Wu W,
    5. Cheng S,
    6. Dai X,
    7. Zhu X, et al.
    Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy. J Immunother Cancer. 2020; 8: e001437.
  15. 15.↵
    2. Limagne E,
    3. Euvrard R,
    4. Thibaudin M,
    5. Rebe C,
    6. Derangere V,
    7. Chevriaux A, et al.
    Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res. 2016; 76: 5241–52.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Van Cutsem E,
    3. Kohne CH,
    4. Hitre E,
    5. Zaluski J,
    6. Chang Chien CR,
    7. Makhson A, et al.
    Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408–17.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.
    2. Qin S,
    3. Li J,
    4. Wang L,
    5. Xu J,
    6. Cheng Y,
    7. Bai Y, et al.
    Efficacy and tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with RAS wild-type metastatic colorectal cancer: the open-label, randomized, phase III TAILOR trial. J Clin Oncol. 2018; 36: 3031–9.
    OpenUrlCrossRefPubMed
  18. 18.
    2. Douillard JY,
    3. Siena S,
    4. Cassidy J,
    5. Tabernero J,
    6. Burkes R,
    7. Barugel M, et al.
    Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014; 25: 1346–55.
    OpenUrlCrossRefPubMed
  19. 19.
    2. Peeters M,
    3. Price TJ,
    4. Cervantes A,
    5. Sobrero AF,
    6. Ducreux M,
    7. Hotko Y, et al.
    Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28: 4706–13.
    OpenUrlAbstract/FREE Full Text
  20. 20.
    2. Amado RG,
    3. Wolf M,
    4. Peeters M,
    5. Van Cutsem E,
    6. Siena S,
    7. Freeman DJ, et al.
    Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1626–34.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    2. Price TJ,
    3. Peeters M,
    4. Kim TW,
    5. Li J,
    6. Cascinu S,
    7. Ruff P, et al.
    Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014; 15: 569–79.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    2. Parseghian CM,
    3. Napolitano S,
    4. Loree JM,
    5. Kopetz S.
    Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies. Clin Cancer Res. 2019; 25: 6899–908.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Sforza V,
    3. Martinelli E,
    4. Ciardiello F,
    5. Gambardella V,
    6. Napolitano S,
    7. Martini G, et al.
    Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol. 2016; 22: 6345–61.
    OpenUrl
  24. 24.↵
    2. Siravegna G,
    3. Mussolin B,
    4. Buscarino M,
    5. Corti G,
    6. Cassingena A,
    7. Crisafulli G, et al.
    Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015; 21: 827.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Cremolini C,
    3. Rossini D,
    4. Dell’Aquila E,
    5. Lonardi S,
    6. Conca E,
    7. Del Re M, et al.
    Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019; 5: 343–50.
    OpenUrl
  26. 26.↵
    2. Inoue Y,
    3. Hazama S,
    4. Suzuki N,
    5. Tokumitsu Y,
    6. Kanekiyo S,
    7. Tomochika S, et al.
    Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. Cancer Sci. 2017; 108: 455–60.
    OpenUrlCrossRefPubMed
  27. 27.↵
    2. Lian G,
    3. Chen S,
    4. Ouyang M,
    5. Li F,
    6. Chen L,
    7. Yang J.
    Colon cancer cell secretes EGF to promote M2 polarization of TAM through EGFR/PI3K/AKT/mTOR pathway. Technol Cancer Res Treat. 2019; 18: 1533033819849068.
  28. 28.↵
    2. Bakema JE,
    3. van Egmond M.
    Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. Curr Top Microbiol Immunol. 2014; 382: 373–92.
    OpenUrlPubMed
  29. 29.↵
    2. Srivastava RM,
    3. Trivedi S,
    4. Concha-Benavente F,
    5. Hyun-Bae J,
    6. Wang L,
    7. Seethala RR, et al.
    STAT1-induced HLA class I upregulation enhances immunogenicity and clinical response to Anti-EGFR mAb cetuximab therapy in HNC patients. Cancer Immunol Res. 2015; 3: 936–45.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    2. Jie HB,
    3. Schuler PJ,
    4. Lee SC,
    5. Srivastava RM,
    6. Argiris A,
    7. Ferrone S, et al.
    CTLA-4(+) regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015; 75: 2200–10.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    2. Ferris RL,
    3. Lenz HJ,
    4. Trotta AM,
    5. Garcia-Foncillas J,
    6. Schulten J,
    7. Audhuy F, et al.
    Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2018; 63: 48–60.
    OpenUrlCrossRefPubMed
  32. 32.↵
    2. Martinelli E,
    3. Martini G,
    4. Famiglietti V,
    5. Troiani T,
    6. Napolitano S,
    7. Pietrantonio F, et al.
    Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 2021; 7: 1529–35.
    OpenUrl
  33. 33.↵
    2. Lee MS,
    3. Loehrer PJ,
    4. Imanirad I,
    5. Cohen S,
    6. Ciombor KK,
    7. Moore DT, et al.
    Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Clin Oncol. 2021; 39: 7.
    OpenUrl
  34. 34.↵
    2. Zhang W,
    3. Han X,
    4. Yang L,
    5. Song Y,
    6. Xie L,
    7. Gai W, et al.
    Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study. BMC Cancer. 2022; 22: 1104.
    OpenUrl
  35. 35.↵
    2. Zhou X,
    3. Xiao Q,
    4. Fu D,
    5. Zhang H,
    6. Tang Y,
    7. He J, et al.
    Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer. Cancer Biol Med. 2021; 19: 213–28.
    OpenUrl
  36. 36.↵
    2. Yi C,
    3. Chen L,
    4. Lin Z,
    5. Liu L,
    6. Shao W,
    7. Zhang R, et al.
    Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology. 2021; 74: 2544–60.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Tintelnot J,
    3. Ristow I,
    4. Sauer M,
    5. Simnica D,
    6. Schultheiss C,
    7. Scholz R, et al.
    Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer. Front Oncol. 2022; 12: 993611.
  38. 38.↵
    2. Xu X,
    3. Yu Y,
    4. Wang Y,
    5. Cui Y,
    6. Li W,
    7. Liang L, et al.
    Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: preliminary findings of a phase II, single-arm study. J Clin Oncol. 2022; 40: 3566.
    OpenUrl
  39. 39.↵
    2. Van Den Eynde M,
    3. Huyghe N,
    4. De Cuyper A,
    5. Sinapi I,
    6. Ferrier M,
    7. Gilet M, et al.
    Interim analysis of the AVETUXIRI trial: avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)—a proof of concept, open-label, nonrandomized phase IIa study. J Clin Oncol. 2021; 39: 80.
    OpenUrl
  40. 40.↵
    2. Fukuoka S,
    3. Hara H,
    4. Takahashi N,
    5. Kojima T,
    6. Kawazoe A,
    7. Asayama M, et al.
    Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020; 38: 2053–61.
    OpenUrlCrossRefPubMed
  41. 41.↵
    2. Fakih M,
    3. Raghav KPS,
    4. Chang DZ,
    5. Bendell JC,
    6. Larson T,
    7. Cohn AL, et al.
    Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC). J Clin Oncol. 2021; 39: 3560.
    OpenUrl
  42. 42.↵
    2. Kim RD,
    3. Kovari BP,
    4. Martinez M,
    5. Xie H,
    6. Sahin IH,
    7. Mehta R, et al.
    A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022; 169: 93–102.
    OpenUrl
  43. 43.↵
    2. Guo Y,
    3. Zhang W,
    4. Ying J,
    5. Zhang Y,
    6. Pan Y,
    7. Qiu W, et al.
    Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer. J Clin Oncol. 2021; 39: 2514.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords